06.01.11
Looking to develop, acquire and market a range of dietary supplements and other products specifically formulated to meet the unique requirements of cancer patients, Helsinn Group, Lugano, Switzerland, has completed a minority investment in Thorne Research, Inc., which develops and manufactures nutritional supplements marketed through licensed healthcare practitioners. In addition to nutritional supplement products, Helsinn and Thorne will pursue the development of medical information and supportive services for healthcare professionals and their patients. The venture will initially be directed at cancer supportive care, cancer pain management and other areas of oncology, and may ultimately be broadened to other disease areas. The deal will create a dedicated natural products division in cancer supportive care within Thorne Research.